Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey".

Authors :: Yeh ML
Yu ML
Source :: Journal of hepatology [J Hepatol] 2020 Aug; Vol. 73 (2), pp. 462. Date of Electronic Publication: 2020 Apr 20.
Publication Year :: 2020
Abstract: Competing Interests: Conflict of interest Ming-Lung Yu has received research support from Abbvie, Abbott, BMS, Gilead, Merck, and Roche; served as a consultant for Abbvie, Abbott, Ascletis, BMS, Gilead, J&J, Merck, Novartis, Pharmaessential, and Roche; served as a speaker for Abbvie, Abbott, Ascletis, BMS, Gilead, Merck, Pharmaessential and Roche. Ming-Lun Yeh: Nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details.

Subjects :: Antiviral Agents therapeutic use
Hepatitis B virus
Humans
Coinfection drug therapy
Hepatitis B complications
Hepatitis B drug therapy
Hepatitis B, Chronic drug therapy
Hepatitis C, Chronic complications
Hepatitis C, Chronic drug therapy

Full Text Access

Tools